Cancer remains one of the leading causes of death globally (1, 2). Immunotherapy has opened a new era of cancer treatment; however, the therapeutic response to immune checkpoint inhibitors (ICI) in ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...

This study presents national- and state-level prevalence of major modifiable cancer risk factors, human papillomavirus vaccination, and cancer screenings among US adults in the years during and after ...

Despite functional heterogeneity, the high frequency of intratumoral neutrophils predicts poor clinical outcomes. The tumor microenvironment reprograms neutrophils into immunosuppressive subsets that ...

Individual cohorts with prediagnosis blood samples have insufficient sample size for such studies. Thus, we established “Prospective Early Detection Consortium for Ovarian Cancer” (“PREDICT”)—a ...

Mutations of the FGFR family members are frequently observed in metastatic bladder cancer. The development of erdafitinib, a pan-FGFR inhibitor, provided a significant therapeutic advance in bladder ...

AbstractActivating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, ...

Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer (IBC). To identify events in DCIS that lead to invasive cancer, we performed single-cell RNA sequencing on DCIS ...

This population-based cohort study used the Korean Nationwide Health Insurance and Medical Checkup Linkage Database. We included adults (≥20 years) diagnosed with kidney cancer (2010–2020; i.e., ...

Insurance giant Cigna accused Bristol Myers Squibb (BMS) of maintaining a monopoly over Pomalyst (pomalidomide), the pharma company’s $2-billion-a-year immunomodulatory drug for multiple myeloma. In a ...

AbstractColorectal cancer is a heterogeneous disease that develops through a stepwise accumulation, yet the underlying mechanisms at single-cell resolution remain unclear. In this study, we profiled ...